Semaglutide News and Research

RSS
Semaglutide weight loss results linked to diabetes severity

Semaglutide weight loss results linked to diabetes severity

The USPSTF recommend clinicians refer children and adolescents 6 years or older with a high BMI to intensive behavioral interventions

The USPSTF recommend clinicians refer children and adolescents 6 years or older with a high BMI to intensive behavioral interventions

WHO issues medical product alert on falsified semaglutides

WHO issues medical product alert on falsified semaglutides

Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study

Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study

New dietary recommendations for patients on latest anti-obesity medications like Ozempic

New dietary recommendations for patients on latest anti-obesity medications like Ozempic

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Pre-surgery GLP-1 agonists reduce post-operative risks in extreme obesity

Pre-surgery GLP-1 agonists reduce post-operative risks in extreme obesity

Metabolic surgery proven most effective for sustained weight loss over GLP-1 drugs and lifestyle interventions

Metabolic surgery proven most effective for sustained weight loss over GLP-1 drugs and lifestyle interventions

Weight loss drug may change how obese people perceive taste

Weight loss drug may change how obese people perceive taste

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

Taking semaglutide once weekly may lower the chances of kidney disease, says study

Taking semaglutide once weekly may lower the chances of kidney disease, says study

Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patients

Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patients

SELECT trial shows semaglutide reduces kidney decline in obese patients

SELECT trial shows semaglutide reduces kidney decline in obese patients

Sharp uptick in youth using wegovy and ozempic, study reports

Sharp uptick in youth using wegovy and ozempic, study reports

From research to practice: Closing the divide in obesity management

From research to practice: Closing the divide in obesity management

Anti-obesity medications slash heart disease risk in obese patients, study finds

Anti-obesity medications slash heart disease risk in obese patients, study finds

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.